HER2 target therapy
Phase 2
HER2 target therapy is one of 57 therapeutic programs targeting Bile Duct Carcinoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
56
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
70 competitors in Breast Carcinoma
#DrugCompanyPhaseTrials
1Femara
NovartisApproved
Mektovi
PfizerApproved
Tagrisso
AstraZenecaApproved
Piqray
NovartisApproved
Tykerb
NovartisApproved
Trexall
Jazz PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Lupron
Sun Pharmaceutical Industries, Inc.Approved
Jakafi
IncyteApproved
Adriamycin
PfizerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Carcinoma1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for HER2 target therapy. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- ZZhejiang University